Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Novel indirubin-3-monoxime derivative I3MV-8b enhances anti-CD38 monoclonal antibody efficacy in multiple myeloma through dual proteasome and HDAC6 inhibition

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXiaoyu ZhangXSXiyue SunYWYijie Wang

Discussion

Loading...

Member takes

Overview

Compound I3MV-8b improves daratumumab efficacy against multiple myeloma, enhancing cytotoxicity and immune response.

Key Points

  • Compound I3MV-8b enhances the efficacy of daratumumab in treating multiple myeloma.
  • Combined therapy significantly improved NK cell cytotoxicity against multiple myeloma cells.
  • Mechanistic studies showed increased CD38 expression and histone acetylation in multiple myeloma cells.
  • Findings support the use of dual inhibition strategies to improve immunotherapy outcomes in multiple myeloma.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d679https://doi.org/10.1182/blood-2025-5708
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma2025 · 1 citations
  2. 2Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma2025 · 1 citations
  3. 3High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy2025
  4. 4Lbl-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed/refractory multiple myeloma2025
  5. 5IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma2025